Research Analysts Offer Predictions for MLYS Q3 Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities researchers at HC Wainwright boosted their Q3 2025 earnings estimates for Mineralys Therapeutics in a report released on Thursday, October 30th. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.58) per share for the quarter, up from their prior forecast of ($0.74). HC Wainwright currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($2.60) EPS, FY2026 earnings at ($2.37) EPS, FY2027 earnings at ($2.36) EPS, FY2028 earnings at ($0.39) EPS and FY2029 earnings at $2.09 EPS.

Other analysts have also issued reports about the stock. The Goldman Sachs Group upped their target price on shares of Mineralys Therapeutics from $32.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. Wall Street Zen upgraded shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Wednesday, October 8th. Jefferies Financial Group increased their price target on shares of Mineralys Therapeutics from $15.00 to $26.00 and gave the company a “hold” rating in a research note on Wednesday, September 3rd. Finally, Bank of America increased their price target on shares of Mineralys Therapeutics from $38.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $45.17.

Mineralys Therapeutics Stock Performance

Shares of MLYS opened at $39.81 on Monday. The company’s 50-day simple moving average is $37.14 and its 200-day simple moving average is $22.49. Mineralys Therapeutics has a 1 year low of $8.24 and a 1 year high of $44.80. The stock has a market capitalization of $2.64 billion, a PE ratio of -11.18 and a beta of 0.40.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Tuesday, August 12th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.12.

Institutional Trading of Mineralys Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. raised its position in shares of Mineralys Therapeutics by 297.5% in the 1st quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company’s stock valued at $25,000 after purchasing an additional 1,190 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Mineralys Therapeutics by 51.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Mineralys Therapeutics by 42.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after purchasing an additional 1,197 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Mineralys Therapeutics in the 2nd quarter valued at approximately $91,000. Finally, Quarry LP acquired a new position in shares of Mineralys Therapeutics in the 1st quarter valued at approximately $111,000. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Insider Buying and Selling

In other news, insider David Malcom Rodman sold 10,369 shares of the firm’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $43.01, for a total value of $445,970.69. Following the completion of the transaction, the insider owned 71,155 shares in the company, valued at $3,060,376.55. This trade represents a 12.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Srinivas Akkaraju purchased 588,235 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was purchased at an average price of $25.50 per share, with a total value of $14,999,992.50. Following the transaction, the director owned 588,235 shares of the company’s stock, valued at approximately $14,999,992.50. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold 58,959 shares of company stock valued at $2,098,393 in the last quarter. Corporate insiders own 33.24% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.